279 results about "Enteral administration" patented technology

The invention provides nutritional supplements for an oral or enteral administration to humans, whether in satisfactory health, or having a medical condition. These supplements can provide humans with a complete, balanced nutrition in a bioavailable form, either as a food supplement or as a meal replacement, and preferably includes one or more slow-digesting carbohydrates that renders them effective in maintaining blood glucose levels at, or returning abnormal blood glucose levels to, normal blood glucose levels. Nutritional supplements within the invention can be employed with humans that are diabetic, borderline diabetic, pregnant and/or lactating, geriatric humans and humans that have, are at risk for, or develop other glucose intolerance or cardiovascular disease.

A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (T_max) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.

This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents_useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.

Disclosed herein are methods and uses for preventing melanoma, reducing progression of atypical nevi, and inducing cell cycle arrest and/or apoptosis in a melanoma cell through oral and enteral administration of sulforaphane to subjects indicated to be at risk due to factor(s) such as medical history of atypical nevi, melanoma, or UV exposure. Sulforaphane can be administered orally as a safe and well-tolerated natural agent as a chemopreventive strategy in individuals with atypical melanocytic nevi.

One aspect of the present invention relates to a liquid edible composition with a pH of more than 6, a viscosity below 600 mPas at a shear rate of 100s⁻¹ and 20° C., and a viscosity of at least 125% of the aforementioned viscosity at a pH below 5 and a temperature of 37° C., the composition comprising at least 0.05 wt. % of pectin having a degree of methoxylation between 2 and 50 and/or of alginate; at least 5 mg calcium per 100 ml; and at least 0.1 wt. % indigestible oligosaccharide having a degree of polymerisation between 2 and 60.

Another aspect of the invention relates to a method for the treatment or prevention of overweight or obesity in mammals, said method comprising the enteral administration to a mammal of an effective amount of the aforementioned composition.

The invention discloses a medical suture that contains an analgesic drug which can slowly release in a body. The suture is combined with the analgesic drug. The medicine administration is simultaneously accomplished during suture, and the medicine is slowly released from the suture, thereby achieving the long term acesodyne effect on the sutured part. Due to the partial medicine administration, the medicine dosage is greatly reduced compared with the whole body medicine administration, and the side effect on the whole body is remarkably reduced while the partial effective pain stop is achieved.

A formulation for enteral administration to a patient is disclosed.

An enteral administration assembly for administering fluids through an enteral device. The administration assembly comprising an inlet, an outlet, and a valve mechanism between the inlet and outlet. The inlet is configured to interlock with only an enteral device to form a sealed connection allowing the passage of fluid between the enteral device and the inlet. The assembly may include a valve or turbulating mechanism comprising a valve and at least one turbulator adapted to change the direction of fluid flowing through the assembly to prevent clogging and flocculation of administered substances.

A delivery device for and method of modulating a condition relating to sodal cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.

The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.

There is provided a carrier for use in enteral administration of biologically active compounds, said carrier comprising an effective amount of one or more phosphate derivatives of one or more electron transfer agents.

Nanoparticles, compositions, and methods for the improved uptake of active agents are disclosed herein. The compositions contain a monodisperse population of nanoparticles, preferably including an active agent, where the nanoparticles are formed from a polymeric material possessing specified bioadhesion characteristics. Following enteral administration, preferably oral administration, the nanoparticles exhibit total intestinal uptakes of greater than 20%, preferably greater than 45%, more preferably greater than 65%. When compared to uptake of the same composition in the absence of the bioadhesive polymeric material, the nanoparticles have significantly increased uptake with intestinal uptake of the increased by more than 100%, preferably even greater than 500%. Further disclosed herein is a method of producing multi-walled nanoparticles, as well as methods of using thereof. Multi-walled particles prepared using the method disclosed herein are useful for controlling the release of active agents.

The present invention provides pharmaceutical compositions of acetylsalicylic acid and omega-3 oils which enable safe and stable oral administration within the range of the narrow therapeutic index prescribed for the prevention of alterations of the cardiovascular system.

This invention concerns an enhanced green tea based product for oral use whereby the nutritional and health benefits of green tea, and additives which shall include some combination of flavoring, preservatives, caffeine, humectants, and water, can be ingested and absorbed by the user.

This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C- terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded in pairs to form two disulfide bonds, wherein the N-terminus of the corresponding linear/non-cyclised conotoxin peptide is linked to the C-terminus by a peptide linker, in a vehicle which is pharmaceutically suitable for oral or enteral administration.

Methods and devices for orally administering fluids and medical instrumentation to individuals for the promotion of health are disclosed. An apparatus is described comprising a pacifier configured to hold fluid and configured for sucking. In some embodiments, the apparatus includes a balloon positioned within a cavity of the pacifier. The balloon is configured to facilitate expulsion of the fluid from the cavity and to limit a user's ingestion of air. In other embodiments, the apparatus includes a cartridge or ampoule configured to store a fluid and expel the fluid through the pacifier. Systems are disclosed which include the pacifier apparatus, a known quantity of fluid or powder, and sterile packaging. Other systems are disclosed whereby various attachments, both medical and non-medical, couple to the apparatus. Methods of using and methods of manufacturing are also disclosed.

The invention belongs to the field of pharmaceutical preparations and relates to an in-situ gel sustained-release preparation which is used for vaginal administration and has high drug loading and a preparation method of the in-situ gel sustained-release preparation. The preparation is formed by an effective dose of drugs, a thermosensitive gel matrix material, a suspending agent and water or a buffer solution, wherein the drugs are suitable for vaginal administration, the thermosensitive gel matrix material is poloxamer, and the suspending agent is xanthan gum; and the suspending agent, i.e. the xanthan gum, does not affect the thermosensitivity of the preparation and can exert an excellent suspending effect on the drugs. The preparation has the advantages of simplicity in preparation, high drug loading, convenience in administration and little irritation, good safety, wide source of raw materials and low cost.